41
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TQ0174 |
Mavorixafor
AMD-070 |
CXCR | Autophagy; GPCR/G Protein; Immunology/Inflammation |
Mavorixafor (AMD-070) 是一种有效的特异性 CXCR4 拮抗剂,对 CXCR4 125I-SDF 结合的 IC50 值为 13 nM。 Mavorixafor 在 MT-4 细胞 (IC50 = 1 nM) 和 PBMC (IC50 = 9 nM) 中抑制 T-tropic HIV-1 (NL4.3 株) 的复制。 | |||
T7208 |
AMD 3465 hexahydrobromide
GENZ-644494 (hexahydrobromide) |
HIV Protease; CXCR | Autophagy; GPCR/G Protein; Immunology/Inflammation; Microbiology/Virology; Proteases/Proteasome |
AMD 3465 hexahydrobromide (GENZ-644494 (hexahydrobromide)) 是一种 CXCR4受体拮抗剂,具有潜在的抗癌和抗 HIV 活性。 | |||
T22565 |
AMD-070 hydrochloride
N-(1H-苯并咪唑-2-基甲基)-N-[(8S)-5,6,7,8-四氢-8-喹啉基]-1,4-丁二胺单盐酸盐 |
CXCR | Autophagy; GPCR/G Protein; Immunology/Inflammation |
AMD-070 hydrochloride 是一种 CXCR4 拮抗剂,可用于抗 HIV。 | |||
T29957 |
AMD-7049
AMD 7049 |
||
AMD-7049 is a biochemical. | |||
T1776 |
Plerixafor
普乐沙福,JM3100,AMD 3100,AMD-3329 |
Virus Protease; HIV Protease; CXCR | Autophagy; GPCR/G Protein; Immunology/Inflammation; Microbiology/Virology; Proteases/Proteasome |
Plerixafor (AMD-3329) 是一种趋化因子受体拮抗剂,可阻断基质细胞衍生因子与细胞受体 CXCR4 的结合。它也是 CXCR7 的变构激动剂,是免疫刺激剂和造血干细胞动员剂,还抑制HIV-1和HIV-2的复制,EC50为 1-10 nM。 | |||
T29958 |
AMD-9370
|
||
AMD-9370 is a biochemical. | |||
T14208 |
AMD 3465
GENZ-644494 |
HIV Protease | Microbiology/Virology; Proteases/Proteasome |
AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM). However, it has no effect on CCR5-using (R5) viruses. AMD 3465 (GENZ-644494) is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4, with IC | |||
T1776L |
Plerixafor octahydrochloride
盐酸普乐沙福,JM3100 octahydrochloride,Plerixafor 8HCl (AMD3100 8HCl),Plerixafor 8HCl,SID791 octahydrochloride,AMD 3100 octahydrochloride,JM 3100 8HCl |
Virus Protease; HIV Protease; CXCR | Autophagy; GPCR/G Protein; Immunology/Inflammation; Microbiology/Virology; Proteases/Proteasome |
Plerixafor octahydrochloride (JM3100 octahydrochloride) 是一种选择性的CXCR4拮抗剂,IC50为 44 nM。Plerixafor 是一种具有造血干细胞动员活性的双环霉素。 | |||
T21323 |
Picoplatin
NX 473,AMD-473,AMD473,NX-473,NX473,AMD 473 |
||
Picoplatin has a broad spectrum of antineoplastic activity and is designed to overcome platinum drug resistance. Picoplatin alkylates DNA, forming both intra- and inter-strand cross-linkages, resulting in the inhibition of DNA replication and transcriptio | |||
T10296 |
Mavorixafor trihydrochloride
AMD-070 trihydrochloride |
HIV Protease | Microbiology/Virology; Proteases/Proteasome |
Mavorixafor trihydrochloride is a selective and orally available CXCR4 antagonist (IC50: 13 nM against CXCR4 125I-SDF binding) and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs (IC50s: 1 and 9 nM). | |||
T69583 | AMD-3451 trihydrochloride | ||
AMD-3451 trihydrochloride is a CCR5/CXCR4 dual antagonist that may be useful in the treatment of HIV. | |||
T70260 |
AMD-3329 hydrobromide
|
||
AMD-3329 hydrobromide is a biochemical in the class of potent and selective anti-HIV-1 and HIV-2 agents that inhibit virus replication by binding to the chemokine receptor CXCR4, the co-receptor for entry of X4 viruses. | |||
T70259 | AMD-3329 free base | ||
AMD-3329 free base is a biochemical in the class of potent and selective anti-HIV-1 and HIV-2 agents that inhibit virus replication by binding to the chemokine receptor CXCR4, the co-receptor for entry of X4 viruses. | |||
T69582 |
AMD-3451 free base
|
||
AMD-3451 free base is a dual CCR5/CXCR4 antagonist which may be useful in the treatment of a wide variety of R5, R5/X4, and X4 strains of human immunodeficiency virus type 1 (HIV-1) and HIV-2. AMD3451 is the first low-molecular-weight anti-HIV agent with selective HIV coreceptor, CCR5 and CXCR4, interaction. | |||
T8574 |
SPHINX
|
Others | Others |
SPHINX 是新一代的 SPRK1抑制剂。 | |||
T9928 |
Ranibizumab
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Ranibizumab 是一种人源化单克隆抗体片段,旨在靶向和抑制血管内皮生长因子 (VEGF),包括 VEGF110、VEGF121 和 VEGF165。 Ranibizumab 选择性靶向和中和 VEGF-A 同工型的能力使其成为湿性年龄相关性黄斑变性 (AMD) 研究和治疗策略的重要组成部分。 | |||
T23716 |
AMDE-1
AMDE 1 |
Autophagy | Autophagy |
AMDE-1 是一种自噬调节剂,以 Atg5 依赖性方式触发自噬。 AMDE-1 将 Atg16 募集到自噬体前位点并导致 LC3 脂化。 | |||
T69725 |
Amdakefalin
|
||
Amdakefalin is a μ and δ opioid receptors agonist that acts as an analgesic. | |||
T39327 |
Amdizalisib
Amdizalisib,HMPL-689 |
||
Amdizalisib is a PI3K inhibitor and used for the research of inflammatory disease, autoimmune disease or cancer. | |||
T26615 |
Amdoxovir
AMDX,DAPD |
||
Amdoxovir is a reverse transcriptase inhibitor. | |||
T29959 |
Amdinocillin methylacetate
Mecillinam acetylmethyl ester |
||
Amdinocillin methylacetate is a Synthetic penicillin. | |||
T13157 |
TG 100801
TG100801,TG 100572 |
VEGFR; Src | Angiogenesis; Tyrosine Kinase/Adaptors |
TG 100801 是 VEGFr2 和 Src 家族(Src 和 YES)激酶的双重抑制剂,是治疗年龄相关性黄斑变性(AMD)的候选化合物。 | |||
T3306 |
PF-04418948
PF 04418948,PF04418948 |
Prostaglandin Receptor | GPCR/G Protein; Immunology/Inflammation |
PF-04418948 是一种可口服的,选择性的前列腺素EP2受体拮抗剂,IC50为16 nM。 | |||
T7493 |
AG-13958
AG-013958,N-[2-氟-5-[[3-[(1E)-2-(2-吡啶基)乙烯基]-1H-吲唑-6-基]氨基]苯基]-1,3-二甲基-1H-吡唑-5-甲酰胺 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
AG-13958 (AG-013958) 是 VEGFR 酪氨酸激酶抑制剂,可用于年龄相关性黄斑变性 (AMD) 的脉络膜新生血管形成的研究。 | |||
T69452 |
AG-13958 monohydrochloride
|
||
AG-13958 monohydrochloride is the HCl salt of AG-13958 --- a VEGFA inhibitor potentially for the treatment of age-related macular degeneration. Neovascular AMD, a subtype characterized by the growth of new, pathologic blood vessels, results in most of the cases of severe and rapid vision loss associated with AMD. A critical activator of angiogenesis in neovascular AMD is VEGF. | |||
T28008 |
MDVN1003
MDVN 1003,MDVN-1003 |
||
MDVN1003 is a potent inhibitor of BTK amd PI3Kδ, two proteins regulated by the B cell receptor (BCR) that drive the growth of many NHLs. MDVN1003 induces cell death in a B cell lymphoma cell line but not in an irrelevant erythroblast cell line. | |||
T74551 |
Avacincaptad pegol sodium
|
||
Avacincaptad pegol (ARC1905) 是一种靶向补体因子5 (C5)的核酸适配体,抑制C5剪切为C5a 和C5b。Avacincaptad pegol 被用于研究与年龄相关的黄斑变性(AMD)。 | |||
T39706 |
Pegaptanib sodium
|
||
Pegaptanib sodium, an RNA aptamer specifically targeting vascular endothelial growth factor (VEGF)-165, holds great promise for investigating neovascular age-related macular degeneration (AMD). | |||
TP1390 |
CEP dipeptide 1
|
||
CEP dipeptide 1, a potent angiogenic compound, exhibits robust activity in promoting angiogenesis. This compound is specifically implicated in the pathogenesis of age-related macular degeneration (AMD). | |||
T77016 | Galegenimab | ||
Galegenimab (FHTR 2163; RG 6147; RO 7171009),一种抗 HTRA1抗体片段。Galegenimab 可用于年龄相关性黄斑变性 (AMD) 研究。 | |||
TP1464 |
Risuteganib hydrochloride
|
||
Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retin | |||
T76987 | Tarcocimab | ||
Tarcocimab (OG1953) 是一种人源化抗VEGFA 单克隆抗体 (IgG1 型)。Tarcocimab 可用于视网膜静脉阻塞 (RVO) 和湿性老年性黄斑变性 (AMD) 的研究。 | |||
T74552 | Non-PEGylated/naked ARC1905 | ||
Non-PEGylated/naked ARC1905 是一种没有偶联PEG 的靶向补体因子5 (C5)的核酸适配体,抑制C5剪切为C5a 和C5b。Non-PEGylated/naked ARC1905 被用于研究与年龄相关的黄斑变性(AMD)。 | |||
T75156L | Bevasiranib sodium | ||
Bevasiranib sodium 是一种siRNA,可沉默产生血管内皮生长因子(VEGF)的基因。VEGF 在脉络膜新生血管形成(choroidal neo-vascularization, CNV)的发病机制中起着关键作用,而CNV 是湿性年龄相关性黄斑变性(wet age-related macular degeneration, wet AMD)的前兆。 | |||
T79010 | Lp-PLA2-IN-12 | Phospholipase | Metabolism |
Lp-PLA2-IN-12(compound 19)为一种Lp-PLA2抑制剂,主要应用于神经退行性疾病(如AD、青光眼、AMD)及心血管疾病(诸如动脉粥样硬化)的研究。 | |||
T75156 | Bevasiranib | ||
Bevasiranib 是一种siRNA,可沉默产生血管内皮生长因子(VEGF)的基因。VEGF 在脉络膜新生血管形成(choroidal neo-vascularization, CNV)的发病机制中起着关键作用,而CNV 是湿性年龄相关性黄斑变性(wet age-related macular degeneration, wet AMD)的前兆。 | |||
T76814 | Lampalizumab | ||
Lampalizumab (RG 7417) 为靶向补体通路中补体因子 D (Factor D) 的人源单克隆抗体。通过结合外位点,该药物立体阻断因子 B 进入活性位点,用于老年性黄斑变性 (AMD) 研究。 | |||
T74867 |
UBX1325
|
||
UBX1325 是一种Bcl-xL 抑制剂,可促进衰老细胞的凋亡 (apoptosis)。UBX1325 是一种有效的抗衰老剂,可用于与年龄相关的眼部疾病的研究,如糖尿病性黄斑水肿 (DME)、年龄相关性黄斑变性 (AMD) 和糖尿病性视网膜病变 (DR)。 | |||
T79074 | Lp-PLA2-IN-14 | Phospholipase | Metabolism |
Lp-PLA2-IN-14(Compound 19)是一种选择性的Lp-PLA2抑制剂,其对rhLp-PLA2表现出较高亲和力,pIC50值达到8.4。该化合物主要适用于对抗与神经退行性疾病相关的研究,包括阿尔茨海默病(AD)、青光眼、年龄相关性黄斑变性(AMD),以及心血管疾病如动脉粥样硬化等。 | |||
T63192 | Lp-PLA2-IN-10 | ||
Lp-PLA2-IN-10 是一种有效的脂蛋白相关磷脂酶 A2 (Lp-PLA2) 抑制剂。Lp-PLA2-IN-10 能够用于神经退行性相关疾病的研究,如阿尔茨海默病(AD)、青光眼、年龄相关的黄斑变性 (AMD),或者包括动脉粥样硬化等心血管疾病。Lp-PLA2 曾经被称作血小板活化因子乙酰水解酶 (PAF-AH),是一种参与脂蛋白脂质或磷脂水解的磷脂酶 A2。 | |||
T33267 |
Me6TREN 4HCl
Me6TREN Tetrahydrochloride,Me6-TREN Tetrahydrochloride,Me6 4HCl,Me 6 4HCl,Me-6 4HCl |
||
Me6TREN 4HCl is a potent and efficacious mobilizing agent of hematopoietic stem and progenitor cells (HSPCs) that can act by activating MMP-9 expression and disrupting the SDF-1α/CXCR4 axis, exhibiting more significant mobilizing effects than G-CSF or AMD |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T83915 |
Norbixin hydrate
|
||
Norbixin是一种在B. orellana中发现的类胡萝卜素,具有多样的生物活性。在无细胞测试中,它与过氧化物酶体增殖物激活受体γ (PPARγ)结合(Ki = 1.15 µM)。在心脑血管代谢综合征大鼠模型中,Norbixin (47.7 mg/kg) 能够减轻高血糖、高胰岛素血症和胰岛素抗性,降低血清脂质水平及心脏中硫代巴比妥酸反应性物质(TBARS)和谷胱甘肽(GSH)的水平。在胆固醇诱导的动脉粥样硬化兔模型中,它降低氧化型LDL和主动脉蛋白氧化水平,并减少动脉粥样硬化面积。Norbixin(每天0.1和1 mg/kg)减少汞诱导的大鼠肝细胞和白细胞DNA损伤。此外,它还能预防与年龄相关的黄斑变性(AMD)Abca4-/- Rdh8-/-小鼠模型中的光感受器退化。 |